MedPath

Effect of Alpha Lipoic Acid on Prevention of Diabetic Peripheral Neuropathy

Not Applicable
Conditions
Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications
Registration Number
CTRI/2023/07/054908
Lead Sponsor
Tanuja P Pattankar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Known type 2 diabetics diagnosed at least one year prior to the commencement of study.

Exclusion Criteria

Patients with type 1 DM, Gestational DM and critically ill patients.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in the score of Total Symptom Score (TSS)Timepoint: At Baseline and end of 6 weeks
Secondary Outcome Measures
NameTimeMethod
To assess the reduction in total symptom score of Diabetic peripheral neuropathy after the intervention with alpha lipoic acid which is an anti - oxidant seems to delay or reverse peripheral diabetic neuropathy at the begining of the study, after 5 weeks and after 3 months.Timepoint: baseline data, after 5 weeks, after 3 months.
© Copyright 2025. All Rights Reserved by MedPath